Form 8-K - Current report:
SEC Accession No. 0000950170-24-122771
Filing Date
2024-11-07
Accepted
2024-11-07 07:05:08
Documents
15
Period of Report
2024-11-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 2.02: Results of Operations and Financial Condition
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K gern-20241101.htm   iXBRL 8-K 79096
2 EX-99.1 gern-ex99_1.htm EX-99.1 216949
3 EX-99.2 gern-ex99_2.htm EX-99.2 23688
4 GRAPHIC img50521483_0.jpg GRAPHIC 56707
5 GRAPHIC img51445004_0.jpg GRAPHIC 56707
  Complete submission text file 0000950170-24-122771.txt   622149

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT gern-20241101.xsd EX-101.SCH 27898
17 EXTRACTED XBRL INSTANCE DOCUMENT gern-20241101_htm.xml XML 4698
Mailing Address 919 EAST HILLSDALE BOULEVARD SUITE 250 FOSTER CITY CA 94404
Business Address 919 EAST HILLSDALE BOULEVARD SUITE 250 FOSTER CITY CA 94404 6504737700
GERON CORP (Filer) CIK: 0000886744 (see all company filings)

EIN.: 752287752 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-20859 | Film No.: 241433090
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)